Meet
Luke Frazier

Luke Frazier supports a range of clients with evidence-based research and analysis on federal and state healthcare policy developments.

He applies his background in public policy and healthcare public affairs advising clients on the impact of policy to industry, with a particular focus on federal and state vaccine policy as well as Medicare Part B.

Prior to joining Avalere, Luke held a variety of internship positions, including an apprenticeship with Schmidt Public Affairs where he drafted healthcare issue briefs and opinion editorials that were placed in major national publications and crafted messaging strategy for client campaigns. Additionally, he interned in the offices of Senator Tina Smith and Governor Mark Dayton where he worked in the areas of healthcare, agriculture, and Native American affairs researching policy issues and briefing staff on relevant topics.

Luke has a BA in international affairs from the George Washington University.

Authored Content

January 21, 2021 | Insights & Analysis > Drug Pricing

MFN Model Would Have Had a Major Impact on Certain Providers
New Avalere analysis finds that the the Most Favored Nation (MFN) Model would have a significant negative impact on Medicare providers that furnish Part B drugs—especially in oncology and rheumatology—and those in rural areas.
October 27, 2020 | Podcasts > COVID-19 Intel Center

Podcast: Designing Pull Funding for a COVID-19 Vaccine
Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study in which a simulation was used to determine whether pull funding could overcome issues related to speed, scaling, and pricing for a COVID-19 vaccine.
September 17, 2020 | Insights & Analysis > Drug Pricing

“Most Favored Nation” EO Creates New Questions on International Prices
On September 13, the Trump Administration released the much-anticipated “Most Favored Nation” (MFN) Executive Order (EO), calling for models that would cap the price Medicare pays for select Part B and D drugs. The President’s EO underscores the administration’s continued focus on reducing prescription drug price disparities between the US and other developed countries.